- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
Other
Principal Investigator(s)
Ariane van der Straten
Objective
This study is primarily exploratory and is designed to both identify factors that may have affected participant adherence to study product in VOICE, and describe how sexual behaviors, such as anal sex, may have had an effect on product efficacy. As such there is no specific hypothesis that is being tested.
Results: While there was interest in a variety of potential PrEP product formulations, a majority of VOICE-D participants preferred long-acting methods. More research is needed to gain insight into end-users' product formulation preference to inform messaging and market segmentation for different PrEP products and resources to invest in products that target populations are most interested in using.
Last updated May 15, 2021
Prevention Option(s)
Microbicides
PrEP
Observational
Retospective Cohort
Official Code
Related Publications
Trial Sponsors
MTN; NIAID (DAIDS-ES: 11893); NIH (5UM1AI068633) ; NICHD; NIMH
December 2012
March 2014
Date of Enrollment Completion
March 19, 2014
Enrollment
219
18
Years
45
Years
Population
Women
Sites
Isipingo CRS
Westville, KwaZulu-Natal
South Africa
Overport CRS
Asherville, KwaZulu-Natal
South Africa
MUJHU CARE LTD CRS
Kampala
Uganda
Seke South Clinical Research Site
Harare
Zimbabwe
Zengeza 3 Clinic
Harare
Zimbabwe